Triple-negative breast cancer (TNBC) is infiltrating breast cancer with negative estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expressions, which renders it unresponsive to conventional anti-hormonal therapy and anti-HER2-targeted treatments (1). Here, ERBB2 is linked to breast carcinoma.